Theme watch · accelerating
gene therapy and rare-disease stocks to watch
As of 2026-07-15
Real FDA U-turn (AMT-130 BLA Q3) but binary post-5x into a just-priced $225M dilution; already hold immunology via KYMR.
First-ever-approval-for-microcystic-lymphatic-malformations narrative accelerating and de-risked: SELVA hit its endpoint (Feb 24, 2026), FDA…
Mitapivat SCD label-expansion re-rate: positive RISE UP Phase 3 (Jun 15) + FDA Priority Review acceptance (Jul 7, ~+15%) + same-day PT cluster to…
NGN-401 Rett-syndrome gene-therapy narrative re-accelerated on the 2026-06-29 low-dose data update, strong enough to place a $125M raise at $30…
Next-gen DMD gene therapy filling the vacuum from Sarepta Elevidys's safety collapse; SGT-003 clean across 40 dosed (no DILI/TMA/myocarditis, May…
Post-setrusumab-failure reset is now a cleaner two-shot gene-therapy story: DTX401 (GSD Ia) PDUFA ~Aug 23 and UX111 (Sanfilippo A) PDUFA ~Sep 19…
Post-crash gene-therapy rebuild: first commercial approval (KRESLADI/LAD-I) plus a non-dilutive $180M PRV sale (closed 2026-06-12) fund it into Q2…
"3-mo price move" is the stock's market price change, not an orbyd return.
How this page is built
These are the names orbyd covers in the gene therapy and rare-disease stocks cluster — each with a dated research dossier. Names currently on the move rank first by 3-month price momentum, then the rest of the covered roster. Cluster membership is assigned by a frontier model, currently read as accelerating.
New cluster emerging from the biotech bid gene-therapy and rare-disease names (uniQure, Rocket, Solid, Neurogene, Dyne, Ultragenyx, Agios) all carrying strong 1m momentum on quiet headlines; early-stage narrative separate from oncology.
Questions
- What gene therapy and rare-disease stocks does orbyd cover?
- As of 2026-07-15, the gene therapy and rare-disease stocks orbyd tracks are led by QURE, PVLA, AGIO, NGNE, each with a dated research dossier. Names already moving rank first by 3-month price momentum; this is research, not a recommendation.
- Is the gene therapy and rare-disease stocks theme accelerating or slowing?
- orbyd's model reads this cluster as accelerating as of 2026-07-15. New cluster emerging from the biotech bid gene-therapy and rare-disease names (uniQure, Rocket, Solid, Neurogene, Dyne, Ultragenyx, Agios) all carrying strong 1m momentum on quiet headlines; early-stage narrative separate from oncology.
- How does orbyd rank gene therapy and rare-disease stocks?
- Every name links to its dated research dossier. Those currently on the move rank first by cross-sectional 3-month price momentum, then the rest of the covered roster by conviction. Methodology is open; this is research, not advice.
Related
As of 2026-07-15 · research, not advice.